Semaglutide eye side effects: what to watch for and when to act

What is NAION, and what does the research actually say?

NAION stands for non-arteritic anterior ischaemic optic neuropathy, a condition where blood supply to the optic nerve is suddenly reduced, damaging the nerve and causing permanent vision loss in the affected eye. It is rare in the general population, but a 2024 study published in JAMA Ophthalmology attracted significant attention by finding a higher proportion of NAION cases among people with type 2 diabetes or obesity who had been prescribed semaglutide, compared with those on other medicines. That finding led to wider public concern, and understandably so.

The NHS medicines guidance on semaglutide notes vision changes as side effects that warrant clinical attention. It is worth being clear about what the study did and did not establish: an observational association is not the same as confirmed causation. People who develop obesity-related cardiovascular risk factors are themselves at higher baseline risk of vascular events, including optic nerve ischaemia. Researchers are actively working to understand whether semaglutide raises that risk independently, or whether the association reflects the population using it. No regulatory authority had issued a specific new warning confirming a causal link as of the time of writing, though the signal is being monitored.

The practical implication is not to panic, but to be informed. If you have a history of NAION, a small optic disc, or other significant eye disease, that is a conversation to have with your prescriber before starting any GLP-1 medicine. A question our prescribers hear most weeks is whether a past diagnosis of glaucoma or optic nerve issues rules out treatment entirely, the answer depends on individual history and is worth discussing properly rather than assuming either way.

Other eye-related changes reported during semaglutide treatment

NAION is not the only eye-related concern associated with GLP-1 medicines. Diabetic retinopathy (damage to the retina's blood vessels caused by long-term high blood sugar) can appear to worsen in the early months of treatment in people with pre-existing retinopathy. This is thought to happen because rapid drops in blood glucose can temporarily stress already-compromised retinal vessels. It is a known phenomenon with glucose-lowering treatments more broadly, not unique to semaglutide. Anyone with existing retinopathy should flag this to their optometrist and diabetes team before starting treatment.

Some people also report blurred vision in the early weeks of treatment, and our dedicated guide to semaglutide side effects affecting the eyes explains why this happens and what to watch for. This is often transient and related to fluid shifts as blood glucose levels change, similar effects are seen when blood sugar is first brought under control with any intervention. It tends to resolve as the body adjusts, but it should still be reported to a prescriber rather than managed in silence. For a fuller picture of the range of effects linked to this medicine, the broader semaglutide side-effect profile covers the whole spectrum from common gastrointestinal symptoms to rarer reports. There is also a detailed look at Wegovy-specific eye concerns if your query is about the weight-loss formulation specifically.

Monocular vision loss, visual field changes, or eye pain are not in the category of symptoms to monitor at home. They warrant same-day contact with an eye emergency unit or A&E.

When to get medical help without delay

This is the clearest section on the page, and it should be. Seek urgent medical attention if you experience sudden loss of vision in one or both eyes, a new visual field defect (a patch of missing vision), eye pain, or a dramatic change in the clarity of your sight that comes on quickly. These symptoms are not explained away by semaglutide's common gastrointestinal side-effect profile, they need clinical assessment fast, because conditions like NAION can cause permanent damage within hours if not addressed.

For any unexpected or worsening symptoms you think may be related to your medicine, the MHRA Yellow Card scheme allows patients to report suspected side effects directly. This matters: real-world reporting is how regulators track rare signals that clinical trials may not have been large enough to detect. You can also contact your prescriber or ophthalmologist. If you are a current patient with questions, the nume aftercare team is available seven days a week. Stopping treatment suddenly without clinical guidance is not advised, how to handle a side effect is a conversation, not a solo decision. The guide to managing semaglutide side effects covers the practical steps for the more common effects, and when stopping or pausing treatment might be clinically appropriate.

How suitability is assessed at the consultation stage

Semaglutide as a weight-loss treatment (prescribed as Wegovy in the UK) is a prescription-only medicine. That prescription follows a clinical assessment, not an automated checklist. At nume, a GPhC-registered Independent Prescriber personally reviews every consultation, looking at the full clinical picture: current conditions, medications, and relevant history including eye health. The NICE recommendation for semaglutide under TA875 establishes the framework for NHS use, and eligibility thresholds guide private prescribing too.

BMI and a weight-related condition are the starting criteria, broadly, a BMI of 30 or above, or 27 or above with a relevant comorbidity such as high blood pressure or prediabetes. But BMI alone never settles the question. Eye history, current medications, and other factors all inform whether Wegovy is the right choice, what monitoring is sensible, and what alternatives might suit better. The free consultation at nume is where that conversation happens, with a real clinician and no obligation to proceed. Pricing context for those who want to plan ahead is on the Wegovy pricing page.